Our results demonstrate the significance of a complex evaluation of novel cardiovascular risk factors in HeFH patients and highlight the importance of further studies to clarify the consequences of low SDF-1 concentrations in FH. The gene discussed is CXCL12; the disease is familial hyperaldosteronism.